# Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Study · id `cardio:ct-nct01499082` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01499082](<https://clinicaltrials.gov/study/NCT01499082>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01499082

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 807 participants.

## Technical summary

Registry record NCT01499082. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2015-04-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 807 participants (enrolled count; ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Results first posted: 2015-04-23 (ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Estonia; Finland; France; Germany; Hungary; Latvia; Mexico; Netherlands; Romania; South Africa (ClinicalTrials.gov record NCT01499082, source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01499082-2022-03-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
- Acronym: EDITION I
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): HOE901-U300 (new formulation of insulin glargine)
- Intervention (Drug): Lantus (insulin glargine)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) (`cardio:pubmed-25078900`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 00380a30921ceb8b6ea94e59a094fcbd683eb36db5481f95a04a00183d230986
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
